Bita Nickkholgh,Joseph McGrath,Sivanandane Sittadjody et al.
Bita Nickkholgh et al.
The MAX (MYC-associated protein X) was discovered as an obligate heterodimer of MYC, a protein product of a prolific proto-oncogene that is dysregulated in over three-fourths of cancers. Targeting MYC directly is fraught with challenges due...
Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes [0.03%]
空间蓝图揭示结直肠癌中缺氧间质细胞程序决定转移还是生长并预测预后
Mingkai Chen,Juan Yang,Jin Wang et al.
Mingkai Chen et al.
The tumor microenvironment (TME) critically influences colorectal cancer (CRC) progression, but its spatial organization and functional impact remain incompletely understood. We integrated single-cell transcriptomics (412,208 cells) with sp...
A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors [0.03%]
TRK-950（抗CAPRIN-1抗体）单药及联合纳武利尤单抗治疗日本晚期实体瘤患者的I期研究
Takafumi Koyama,Kan Yonemori,Jun Sato et al.
Takafumi Koyama et al.
CAPRIN-1 is a cytoplasmic phosphoprotein strongly expressed on the membrane surface of cancer cells in most solid tumors but not on normal cells. TRK-950 is a first-in-class humanized antibody that targets CAPRIN-1 and demonstrates antitumo...
Recent progress of dendritic cell-derived exosomes in tumor immunotherapy [0.03%]
树突状细胞源性外泌体在肿瘤免疫治疗中的新进展
Baiyan Wang,Yirui Hu,Yujia Zhou et al.
Baiyan Wang et al.
Despite advancements in conventional tumor therapies including surgery and chemotherapy, effective cancer management remains challenging due to treatment resistance and tumor microenvironment complexity. Dendritic cell (DC)-based vaccines, ...
Clinical pharmacokinetic characteristics and the food effect of radotinib [0.03%]
瑞戈非尼的临床药动学特征及食物效应研究
Yerin Lee,Jiwon Kim,Minseo Kang et al.
Yerin Lee et al.
Radotinib is a second-generation tyrosine kinase inhibitor that selectively targets BCR-ABL1 and is used for the treatment of chronic myeloid leukemia (CML). This study aimed to evaluate the clinical pharmacokinetic characteristics and the ...
Crocetin suppresses colorectal cancer progression by targeting TGM2 and inhibiting the JAK2/STAT3 pathway [0.03%]
万寿菊素通过靶向TGM2和抑制JAK2/STAT3信号通路来抑制结直肠癌进展
Shuo Chen,Weijun Su,Kai Wang et al.
Shuo Chen et al.
Background: Colorectal cancer (CRC) is a major health threat with limited therapies for advanced stages. Crocetin, a natural compound from saffron, has broad anticancer potential, but its mechanisms in CRC are unclear. ...
Network pharmacology-based therapeutic intervention of Mentha arvensis targeting cancer and doxorubicin-induced cardiotoxicity [0.03%]
基于网络药理学的薄荷脑治疗癌症和多柔比星诱导的心脏毒性的研究
Satinder Kaur,Umashanker Navik,Gurjit Kaur Bhatti et al.
Satinder Kaur et al.
Background: Doxorubicin (Dox) is a widely used chemotherapeutic agent effective against hematological malignancies and solid tumors, including leukemia, breast and bladder cancers, lymphomas, and Kaposi's sarcoma. Despite...
Transforming cisplatin therapy: a localized, injectable poly(anhydride-ester) depot for safer and more effective head and neck cancer treatment [0.03%]
转化顺铂疗法：一种局部注射的聚（酸酐酯）植入剂用于安全且有效的头颈癌治疗
Omiya Ali Hasan,Randa Mohammed Zaki,Obaid Afzal et al.
Omiya Ali Hasan et al.
Head and neck cancer patients often receive systemic cisplatin chemotherapy, which is effective but limited by severe toxicity and poor tumor selectivity. An injectable, biodegradable polyanhydride polymer derived from sebacic acid (SA) and...
Prognostic factors and outcome measures after BRAF-directed targeted therapy of unresectable metastatic BRAFV600E colorectal cancer: a study cohort-level analysis [0.03%]
针对不可手术的BRAF V600E突变型转移性结直肠癌的BRAF导向靶向治疗的预后因素和疗效评估：基于队列研究的分析
Giuseppe A Colloca,Antonella Venturino
Giuseppe A Colloca
BRAFV600E mutation in metastatic colorectal cancer (mCRC) is associated with a poor prognosis. BRAFV600E inhibitors (BRAFi) plus EGFR inhibitors + / - MEK inhibitors regimens prolonged overall survival (OS), but prognosis remains heterogene...
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534 [0.03%]
ONCT-534双效雄激素受体抑制剂Ⅰ期多中心临床及生物标志物研究
Matthew R Chrostek,James Robinson,Rajesh Krishnan et al.
Matthew R Chrostek et al.
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that combines AR antagonism and degradation via N-terminal domain binding, additionally targeting AR splice variants. In this study patients received ONCT-534 daily ranging from ...